MRNA vs NIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NIO Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NIO Inc. American depositary shares, each representing one Class A ordinary share (NIO) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus NIO at 48.5x Forward P/E and -3.3% operating margin (+69.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against NIO sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | NIO Revenue | MRNA Op. Margin | NIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $720M | -306.0% | -193.8% | NIO |
| FY2019 | $60M | $1.12B | -906.8% | -141.6% | NIO |
| FY2020 | $800M | $2.49B | -95.0% | -28.3% | NIO |
| FY2021 | $18.5B | $5.67B | 72.0% | -12.4% | MRNA |
| FY2022 | $19.3B | $7.14B | 48.9% | -31.7% | MRNA |
| FY2023 | $6.85B | $7.83B | -61.9% | -40.7% | NIO |
| FY2024 | $3.24B | $9.01B | -121.9% | -33.3% | NIO |
| FY2025 | $1.94B | $12.5B | -158.1% | -16.0% | NIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | NIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $6.3B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 48.5x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 48.5x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +69.1% | Higher Growth | NIO |
| Operating Margin (TTM) Profitability | -80.8% | -3.3% | Higher Margin | NIO |
| Net Profit Margin Profitability | -110.5% | -4.2% | Higher Margin | NIO |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -45.3% | Higher ROE | MRNA |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 0% ($2โ$7) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 1.31ฮฒ ยท 53% Vol | Lower Realized Risk | NIO |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 43.9 / 100 (HOLD) | Higher Composite | NIO |